Skip to main content
ERAS
NASDAQ Life Sciences

Erasca Pulls Forward Phase 3 Pancreatic Trial to 1H 2027 After 44% ORR Data

Tom Rudovsky · Reported by Benzinga
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$14.01
Mkt Cap
$4.938B
52W Low
$2.75
52W High
$24.28
52W Position info
409% above low
Off High info
42% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

ERAS has more than doubled off its 52-week low of $2.75.

Summary

Erasca is moving its planned Phase 3 first-line pancreatic cancer trial into the first half of 2027, pulled forward on the strength of updated Phase 1 data for ERAS-0015. The pan-RAS molecular glue hit a 44% confirmed ORR in 25 second-line-or-later PDAC patients at 32 mg daily, including 69% in the 13 patients with KRAS G12D or G12V mutations. Responses also showed up outside pancreatic cancer: 60% confirmed ORR in second/third-line NSCLC and 75% in biliary tract cancer. Safety held up — no dose-limiting toxicities, no discontinuations among the 54 patients on 32 mg, and early combination arms with gemcitabine/nab-paclitaxel, pembrolizumab and panitumumab produced no unexpected signals. Separately, initial Phase 1 data for pan-KRAS inhibitor ERAS-4001 showed mostly low-grade adverse events and early antitumor activity, and nonclinical work supports pairing the two drugs. The stock was down 3.06% at $13.79 Friday morning despite the data, so the market is not paying up yet. Next milestones: the 2L+ NSCLC and 1L PDAC trials in 1H 2027, a 1L NSCLC Phase 3 in late 2027 to early 2028, and an ERAS-0015/ERAS-4001 combination escalation trial in 2027.

At the time of this announcement, ERAS was trading at $14.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.9B. The 52-week trading range was $2.75 to $24.28. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Benzinga.


Price Chart

Share this article

Copied!

ERAS - Latest Insights

ERAS
Nov 20, 2026, 7:05 AM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $13.75
Real-time Price: $13.61 info
Change: -$0.140 (-1%) info
Market Cap: $4.789B info
ERAS
Nov 20, 2026, 7:00 AM EST
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $13.99
Real-time Price: $13.61 info
Change: -$0.380 (-3%) info
Market Cap: $4.789B info
ERAS
Nov 17, 2026, 6:40 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $13.99
Real-time Price: $13.61 info
Change: -$0.380 (-3%) info
Market Cap: $4.789B info
ERAS
Nov 12, 2026, 4:03 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $15.78
Real-time Price: $13.61 info
Change: -$2.17 (-14%) info
Market Cap: $4.789B info
ERAS
Nov 12, 2026, 4:01 PM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $15.78
Real-time Price: $13.61 info
Change: -$2.17 (-14%) info
Market Cap: $4.789B info